Abstract Number: 2414 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Abatacept in Patients with Early Active Primary Sjögren’s Syndrome – Open-label Extension Phase of a Randomized Controlled Phase III Trial
Background/Purpose: Abatacept (CTLA-4-Ig) targets the CD80/CD86:CD28 co-stimulatory pathway required for full T-cell activation and T-cell dependent activation of B-cells. The Abatacept Sjögren Active Patients phase…Abstract Number: 2415 • 2019 ACR/ARP Annual Meeting
Evaluation of Pharmacokinetics and Immunogenicity Following Subcutaneous Administration of Abatacept in Primary Sjogren ’s Syndrome (pSS) and RA Patients
Background/Purpose: Abatacept (ABA) has proven efficacy in autoimmune diseases and is being evaluated in pSS. The purpose of this investigation was to evaluate the pharmacokinetics…Abstract Number: 2416 • 2019 ACR/ARP Annual Meeting
ALPN-101, a First-in-Class Dual ICOS/CD28 Antagonist, Suppresses Key Effector Mechanisms Associated with Sjögren’s Syndrome
Background/Purpose: ALPN-101 is an Fc fusion protein of a human inducible T cell costimulator ligand (ICOSL) variant immunoglobulin domain (vIgDTM) designed to inhibit simultaneously the…Abstract Number: 2417 • 2019 ACR/ARP Annual Meeting
A Phase 2a Study of MEDI5872 (AMG557), a Fully Human Anti-ICOS Ligand Monoclonal Antibody in Patients with Primary Sjögren’s Syndrome
Background/Purpose: The interaction of inducible T cell costimulatory ligand (ICOSL) and the ICOS receptor is key in the pathogenesis of primary Sjögren’s syndrome (pSS). MEDI5872…Abstract Number: 2418 • 2019 ACR/ARP Annual Meeting
Tofacitinib Inhibits Increased Inflammatory Marker Expression in a Human Salivary Cell Line Deficient in Autophagy: A Model of Sjögren’s Syndrome
Background/Purpose: Sjögren’s syndrome (SS) is an immune-mediated exocrinopathy, where defects in autophagy could contribute to the pathogenesis. Minor labial salivary glands (MLSG) of primary SS…Abstract Number: 2419 • 2019 ACR/ARP Annual Meeting
An ex-vivo Assay to Evaluate the Efficacy of Different Treatments for Inhibiting B Lymphocytes Activation by Salivary Gland Epithelial Cells in Sjögren’s Syndrome
Background/Purpose: Primary Sjögren's syndrome (pSS) is an auto-immune disorder characterized by a chronic hyperactivation of B lymphocytes. We previously showed that salivary gland epithelial cells…Abstract Number: 2420 • 2019 ACR/ARP Annual Meeting
Role of T Follicular Helper Cells and T Peripheral Helper Cells in the Activation of B Cells in Sjögren Syndrome
Background/Purpose: Primary Sjögren's Syndrome (pSS) is a rare systemic autoimmune disease characterized by a dysregulation of cellular and humoral immunity, leading to a hyper-activation of…Abstract Number: 2421 • 2019 ACR/ARP Annual Meeting
Circulating CCR7loPD-1hi Follicular Helper T Cells Indicate Disease Activity and Glandular Inflammation in Patients with Primary Sjögren’s Syndrome
Background/Purpose: Since primary Sjögren’s syndrome (pSS) is an autoummune disease of B cell hyperactivity and pathologic autoantibody response, follicular helper T (Tfh) cells and follicular…Abstract Number: 2422 • 2019 ACR/ARP Annual Meeting
Increased Apoptosis and Compromised Suppressive Capacity of Regulatory T Cells in Primary Sjögren’s Syndrome
Background/Purpose: To investigate the apoptosis and suppressive function of regulatory T cells (Tregs) in primary Sjögren’s syndrome (pSS), and the effect of low-dose IL-2 on apoptosis of Tregs.Methods:…Abstract Number: 2423 • 2019 ACR/ARP Annual Meeting
In Primary Sjogren’s Syndrome (pSS) IL7 Promotes the Crosstalk Between T Lymphocytes and Salivary Gland Epithelial Cells and Participates to IFN Signature
Background/Purpose: pSS is characterized by lymphocytic infiltration of salivary gland epithelial cells (SGEC). This infiltrate is made of T (TL) and B (BL) lymphocytes. SGEC…Abstract Number: 2424 • 2019 ACR/ARP Annual Meeting
RORγt Antagonist Attenuates Experimental Sialadenitis Like Sjögren’s Syndrome via Inhibition of CD25 Expression on CD4+ T Cells
Background/Purpose: Our previous study demonstrated that T cells specific RORγt transgenic-mice under human CD2 promoter (RORγt-Tg mice) developed severe spontaneous sialadenitis like Sjögren’s syndrome (SS)…Abstract Number: 2425 • 2019 ACR/ARP Annual Meeting
The anti-Ro52 Prevalence in the Sjögren’s Syndrome Picture: A Single Center Cross Sectional Study
Background/Purpose: Sjögren syndrome (SjS) is an autoimmune disorder characterized by inflammation and destruction of exocrine glands. The presence of autoantibodies (AA) against the Ro52/TRIM21, an…Abstract Number: 2426 • 2019 ACR/ARP Annual Meeting
Distinct Clinical Characteristics of Anti-Ro/SSA Negative Primary Sjögren’s Syndrome: Data from a Cohort for Sjögren’s Syndrome in Korea
Background/Purpose: To investigate clinical characteristics of patients with primary Sjögren’s syndrome (SS) who were negative for anti-Ro/SSA antibody but positive for minor salivary gland biopsy…Abstract Number: 2427 • 2019 ACR/ARP Annual Meeting
The Positivity for Anti-centromere Antibody Makes Distinct Clinical Features in Primary Sjogren’s Syndrome : Data from a Prospective Korean Nation-wide Cohort
Background/Purpose: To clarify clinical features of primary Sjogren’s syndrome (SS) patients who show the positivity for anti-centromere antibody in Korea.Methods: We assessed 318 patients who…Abstract Number: 2428 • 2019 ACR/ARP Annual Meeting
Serum Myositis Specific/associate Autoantibodies Help Identify Early Connective Tissue Diseases Relevant Interstitial Lung Diseases: A Medical Center Experience
Background/Purpose: Interstitial lung diseases (ILD), a heterogeneous group of pulmonary disorders, originated from idiopathic causes or secondary to certain etiologies, such as infectious diseases, drugs,…
ACR Meeting Abstracts